ALYREF

ALYREF interacts with other mRNA export factors, such as NXF1, NXT1, and UAP56, as well as RNA binding proteins, transcription factors, and RNA helicases to coordinate mRNA export processes.

ALYREF contributes to the regulation of gene expression by influencing the export efficiency of specific mRNA subsets, thereby impacting their translation and protein production.

Targeting ALYREF pharmacologically may offer a means to modulate mRNA export and gene expression, potentially influencing disease-related processes, including cancer progression or viral replication.

ALYREF expression, localization, or activity can be regulated by signaling pathways, such as the PI3K/AKT/mTOR pathway or stress response pathways, to modulate mRNA export under specific conditions.

ALYREF undergoes phosphorylation, acetylation, and methylation, which can regulate its RNA binding affinity, nuclear-cytoplasmic shuttling, or interactions with other proteins.

ALYREF depletion or overexpression can lead to defects in mRNA export, altered gene expression patterns, and impaired cellular processes, such as compromised proliferation, impaired differentiation, or increased sensitivity to stress.

ALYREF dysfunction has been implicated in various diseases, including cancer, neurological disorders, and viral infections. Its altered expression or subcellular localization may serve as diagnostic or prognostic markers in certain disease contexts.

ALYREF plays a crucial role in mRNA export by interacting with mRNA export factors, nuclear pore components, and RNA molecules to facilitate their transport across the nuclear envelope.

ALYREF participates in mRNA surveillance mechanisms, including the recognition and removal of aberrant or misprocessed mRNAs, preventing their export to the cytoplasm.

ALYREF contains RNA recognition motifs (RRMs) that bind to specific RNA sequences or structures, such as exon junction complexes (EJCs) or specific mRNA export elements.